linvemastat
Phase 2Small molecule
linvemastat is one of 21 small molecule programs targeting Asthma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Cinqair
TevaPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Spiriva
Boehringer IngelheimPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
linvemastat
FForesee Pharmaceuticals Co., Ltd.
Phase 2
Lexapro
SShirley Ryan AbilityLab
Preclinical
Ozone
TTanta University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for linvemastat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details